Travere Therapeutics, Inc.
https://travere.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Travere Therapeutics, Inc.
Travere Set For Big Expansion As Filspari Wins Full Approval In IgAN
The drug maker could end up doubling the addressable patient population for Filspari thanks to the new label removing the proteinuria threshold, plus a draft treatment guideline from a kidney disease group.
US FDA September User Fee Calendar Slims Down, Still Boasts More Than Five Novel Agents
New therapies in the wings include two candidates for Niemman-Pick disease type C, a first-in-class antipsychotic, a targeted oncology therapy under Real-Time Oncology Review, and a new drug for gastroparesis.
Fabhalta IgAN Nod Plays Into Novartis’s Long-Term Nephrology Development Plan
US FDA approval in IgAN is just the first step in a much larger renal disease strategy for the company, which includes additional kidney indications for Fabhalta.
Endo En Route To NYSE With Common Stock Exchange Expected Later In 2024
Endo continues to stride its financial revival path, with the latest plans to list common stock on the NYSE. Also, the firm has just launched a generic tiopronin rival to Travere Therapeutics' Thiola.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Nasal
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Desert Gateway, Inc.
- Kyalin Biosciences, Inc.
- Manchester Pharmaceuticals LLC.
- Orphan Technologies Ltd.
- Retrophin, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice